193 related articles for article (PubMed ID: 36923488)
1. Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease.
Magalhaes D; Peyrin-Biroulet L; Estevinho MM; Danese S; Magro F
Therap Adv Gastroenterol; 2023; 16():17562848231155987. PubMed ID: 36923488
[TBL] [Abstract][Full Text] [Related]
2. A Specific Calprotectin Neo-epitope [CPa9-HNE] in Serum from Inflammatory Bowel Disease Patients Is Associated with Neutrophil Activity and Endoscopic Severity.
Mortensen JH; Sinkeviciute D; Manon-Jensen T; Domislović V; McCall K; Thudium CS; Brinar M; Önnerfjord P; Goodyear CS; Krznarić Ž; Karsdal MA; Bay-Jensen AC
J Crohns Colitis; 2022 Sep; 16(9):1447-1460. PubMed ID: 35304895
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. A Serological Neoepitope Biomarker of Neutrophil Elastase-Degraded Calprotectin, Associated with Neutrophil Activity, Identifies Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease More Effectively Than Total Calprotectin.
Hansen AH; Mortensen JH; Rønnow SR; Karsdal MA; Leeming DJ; Sand JMB
J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137658
[TBL] [Abstract][Full Text] [Related]
5. Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease.
Colman RJ; Tsai YT; Jackson K; Boyle BM; Noe JD; Hyams JS; D'Haens GRAM; van Limbergen J; Rosen MJ; Denson LA; Minar P
Inflamm Bowel Dis; 2021 Jun; 27(7):1045-1051. PubMed ID: 32944769
[TBL] [Abstract][Full Text] [Related]
6. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?
Di Ruscio M; Vernia F; Ciccone A; Frieri G; Latella G
Inflamm Bowel Dis; 2017 Dec; 24(1):78-92. PubMed ID: 29272479
[TBL] [Abstract][Full Text] [Related]
7. Serological Biomarkers of Extracellular Matrix Turnover and Neutrophil Activity Are Associated with Long-Term Use of Vedolizumab in Patients with Crohn's Disease.
Alexdottir MS; Bourgonje AR; Karsdal MA; Pehrsson M; Loveikyte R; van Dullemen HM; Visschedijk MC; Festen EAM; Weersma RK; Faber KN; Dijkstra G; Mortensen JH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897710
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis.
Brazzelli M; Aucott L; Aceves-Martins M; Robertson C; Jacobsen E; Imamura M; Poobalan A; Manson P; Scotland G; Kaye C; Sawhney S; Boyers D
Health Technol Assess; 2022 Jan; 26(7):1-286. PubMed ID: 35115079
[TBL] [Abstract][Full Text] [Related]
9. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease.
Verstockt B; Verstockt S; Dehairs J; Ballet V; Blevi H; Wollants WJ; Breynaert C; Van Assche G; Vermeire S; Ferrante M
EBioMedicine; 2019 Feb; 40():733-742. PubMed ID: 30685385
[TBL] [Abstract][Full Text] [Related]
10. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
[TBL] [Abstract][Full Text] [Related]
11. Prognostic biomarkers to identify patients likely to develop severe Crohn's disease: a systematic review.
Halligan S; Boone D; Archer L; Ahmad T; Bloom S; Rodriguez-Justo M; Taylor SA; Mallett S
Health Technol Assess; 2021 Jul; 25(45):1-66. PubMed ID: 34225839
[TBL] [Abstract][Full Text] [Related]
12. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?
Boon GJ; Day AS; Mulder CJ; Gearry RB
World J Gastroenterol; 2015 Oct; 21(40):11469-80. PubMed ID: 26523111
[TBL] [Abstract][Full Text] [Related]
13. Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease.
Thorsvik S; Damås JK; Granlund AV; Flo TH; Bergh K; Østvik AE; Sandvik AK
J Gastroenterol Hepatol; 2017 Jan; 32(1):128-135. PubMed ID: 27640344
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory Bowel Disease and Neutrophil-Lymphocyte Ratio: A Systematic Scoping Review.
Langley BO; Guedry SE; Goldenberg JZ; Hanes DA; Beardsley JA; Ryan JJ
J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575330
[TBL] [Abstract][Full Text] [Related]
15. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
16. Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin.
Cao Y; Dai Y; Zhang L; Wang D; Hu W; Yu Q; Wang X; Yu P; Liu W; Ping Y; Sun T; Sang Y; Liu Z; Chen Y; Tao Z
J Inflamm Res; 2021; 14():6409-6419. PubMed ID: 34880643
[TBL] [Abstract][Full Text] [Related]
17. Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis.
Yang Y; Fu KZ; Pan G
World J Gastrointest Surg; 2024 Jan; 16(1):228-238. PubMed ID: 38328320
[TBL] [Abstract][Full Text] [Related]
18. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
19. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.
Sinopoulou V; Gordon M; Akobeng AK; Gasparetto M; Sammaan M; Vasiliou J; Dovey TM
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013531. PubMed ID: 34844288
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis-the ACERTIVE study.
Magro F; Lopes S; Coelho R; Cotter J; Dias de Castro F; Tavares de Sousa H; Salgado M; Andrade P; Vieira AI; Figueiredo P; Caldeira P; Sousa A; Duarte MA; Ávila F; Silva J; Moleiro J; Mendes S; Giestas S; Ministro P; Sousa P; Gonçalves R; Gonçalves B; Oliveira A; Chagas C; Torres J; Dias CC; Lopes J; Borralho P; Afonso J; Geboes K; Carneiro F;
J Crohns Colitis; 2017 Apr; 11(4):435-444. PubMed ID: 27664275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
